about
Heterocyclic isosters of antimycobacterial salicylanilides.Amino acid derivatives as transdermal permeation enhancers.Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity.Study of hydrophobic properties of biologically active open analogues of flavonoids.A note to the biological activity of benzoxazine derivatives containing the thioxo group.Synthesis and in vitro antifungal activity of 4-substituted phenylguanidinium salts.QSPR modeling of the half-wave potentials of benzoxazines by optimal descriptors calculated with the SMILES.Ceramide analogue 14S24 ((S)-2-tetracosanoylamino-3-hydroxypropionic acid tetradecyl ester) is effective in skin barrier repair in vitro.Synthesis and Biological Activity of Quaternary Ammonium Salt-Type Agents Containing Cholesterol and TerpenesDifferent Phase Behavior and Packing of Ceramides with Long (C16) and Very Long (C24) Acyls in Model Membranes: Infrared Spectroscopy Using Deuterated LipidsCeramides in the Skin Lipid Membranes: Length MattersConformational analysis of 2-hydroxy-2',5'-diazachalconesSynthetic ceramide analogues as skin permeation enhancers: structure-activity relationshipsQSAR study of antimycobacterial activity of quaternary ammonium salts of piperidinylethyl esters of alkoxysubstituted phenylcarbamic acidsThe oriented development of antituberculotics (Part II): halogenated 3-(4-alkylphenyl)-1,3-benzoxazine-2,4-(3H)-dionesAmmonium carbamates as highly active transdermal permeation enhancers with a dual mechanism of actionEffect of ceramide acyl chain length on skin permeability and thermotropic phase behavior of model stratum corneum lipid membranes
P50
Q36135688-D371A8F1-46E4-40FF-895D-E29E986B3AADQ39244244-7983BED8-DBBE-4F60-ABFF-A2F5E9FCA471Q40164131-0255913A-96C0-4DA1-AA84-9D49B557DB3FQ42679951-826BACDB-5859-4B96-BACC-0FDAD2A359A6Q43131172-BBB14C37-3A4C-4FCA-BE43-374D6B01DF87Q44921975-BBF7513C-2B7C-45BF-80DB-20A28E913E7BQ47873171-E2F415D9-306D-4794-9995-CDA0AECB2D93Q52553491-7CC712AC-F9BD-4231-98E9-EA7B090A750DQ58929987-2036C72B-DEDD-4856-98E0-F5E597093691Q60496408-77018CC5-4517-4AD2-9EBE-BCD7DB83A96DQ60496415-C74B084B-CBC1-43F0-91E6-9DC69033FBA5Q74012132-E2922548-8B2E-4BDE-A6C2-F52C4EEAD8D4Q79328408-F192DEA4-F5C9-4BB2-BAED-5C90B72A53A0Q79841920-2D539265-4E3B-45FE-87EA-AE69EF46A6DEQ80363605-E2151A6E-EBAD-48B6-9EB6-C37D8C14EA8BQ82534878-C8F5D74B-01AE-4A96-A418-4BBFC14B7763Q82936979-86C1F0EF-CE2D-4998-A575-62F51A821111
P50
description
researcher ORCID ID = 0000-0001-8911-2620
@en
český farmakolog na Univerzitě Karlově v Hradci Králové
@cs
name
Karel Palát
@ast
Karel Palát
@cs
Karel Palát
@en
Karel Palát
@es
Karel Palát
@nl
Karel Palát
@sl
type
label
Karel Palát
@ast
Karel Palát
@cs
Karel Palát
@en
Karel Palát
@es
Karel Palát
@nl
Karel Palát
@sl
altLabel
Karel Palat
@en
prefLabel
Karel Palát
@ast
Karel Palát
@cs
Karel Palát
@en
Karel Palát
@es
Karel Palát
@nl
Karel Palát
@sl
P214
P106
P19
P21
P214
P31
P496
0000-0001-8911-2620
P569
1957-10-06T00:00:00Z
P691
jn99240000831
P734
P735
P7859
viaf-84106922